Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a chatbot help beat opioid addiction? new trial aims to find out

NCT ID NCT06845878

Symptom relief Sponsor: Dimagi Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests whether an AI chatbot called Suzy can help people recovering from opioid use disorder stay engaged with their care. Over 12 weeks, 55 participants will use the chatbot to prepare for appointments, find community resources, and learn coping techniques. Researchers will measure changes in drug use severity, anxiety, depression, and self-efficacy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chatbot (Suzy)
What this could lead to
If it works, this could provide a low-cost, accessible tool to help people in recovery stay on track and reduce relapse risk.
What could go wrong
This is a small, early-phase trial with only 55 participants, so results may not apply broadly. The chatbot is not a substitute for medical care and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

55 people

The number who actually took part.

Started

Mar 2025

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-65 years old * Comfortable with reading, understanding, and communicating in English * Receiving medication treatment for OUD at MGH? * Able to participate in a remote interview? * Own or have reliable access to Wi-Fi or a cellular network * Willing to use a mobile device to access the chatbot? Exclusion Criteria: * Has any cognitive, visual, or auditory impairments that may prevent the participant from using the chatbot on a mobile device? * Unstable medical condition that compromises the ability to safely participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opiate substitution treatment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opiate substitution treatment Opiate-related disorders

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.